3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Papillary renal cell carcinoma, sporadic
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Interventions
Cyclophosphamide
29
fludarabine
19
Rituximab
15
fludarabine phosphate
12
Specimen Handling
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Lenalidomide
6
Etoposide
6
pirtobrutinib
5
ibrutinib
5
glofitamab
5
axicabtagene ciloleucel
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
venetoclax
4
polatuzumab vedotin
4
Prednisone
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Blood Component Removal
4
Biopsy
4
pembrolizumab
3
daratumumab
3
X-Rays
3
Vincristine
3
Stem Cell Transplantation
3
Interleukin-2
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Non-Hodgkin
×
Erlotinib Hydrochloride
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled